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Abstract
Background: Tobacco smoking is responsible for over 90% of lung cancer cases, and yet the precise molecular alterations
induced by smoking in lung that develop into cancer and impact survival have remained obscure.
Methodology/Principal Findings: We performed gene expression analysis using HG-U133A Affymetrix chips on 135 fresh
frozen tissue samples of adenocarcinoma and paired noninvolved lung tissue from current, former and never smokers, with
biochemically validated smoking information. ANOVA analysis adjusted for potential confounders, multiple testing
procedure, Gene Set Enrichment Analysis, and GO-functional classification were conducted for gene selection. Results were
confirmed in independent adenocarcinoma and non-tumor tissues from two studies. We identified a gene expression
signature characteristic of smoking that includes cell cycle genes, particularly those involved in the mitotic spindle
formation (e.g., NEK2, TTK, PRC1). Expression of these genes strongly differentiated both smokers from non-smokers in lung
tumors and early stage tumor tissue from non-tumor tissue (p,0.001 and fold-change .1.5, for each comparison),
consistent with an important role for this pathway in lung carcinogenesis induced by smoking. These changes persisted
many years after smoking cessation. NEK2 (p,0.001) and TTK (p = 0.002) expression in the noninvolved lung tissue was also
associated with a 3-fold increased risk of mortality from lung adenocarcinoma in smokers.
Conclusions/Significance: Our work provides insight into the smoking-related mechanisms of lung neoplasia, and shows
that the very mitotic genes known to be involved in cancer development are induced by smoking and affect survival. These
genes are candidate targets for chemoprevention and treatment of lung cancer in smokers.
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Introduction
Lung cancer is the leading cause of cancer death worldwide.
Cigarette smoking is responsible for about 90% of lung cancers
and decreases survival,[1] and yet the precise molecular
alterations induced by smoking in lung that develop into cancer
and impact survival have remained obscure. Using Affymetrix
HG-U133A microarrays on 135 fresh frozen adenocarcinoma
and paired non-tumor tissue samples from current, former and
never smokers from the Environment And Genetics in Lung
cancer Etiology (EAGLE) study (http://dceg.cancer.gov/eagle),
we sought to identify the genes that are altered by smoking in
lung, and those, within the smoking signature, that have a role in
lung carcinogenesis and outcome from lung cancer. We chose
adenocarcinoma, the predominant histological subtype of lung
cancer, because it occurs in subjects with no history of smoking
as well as in smokers, providing a range of exposures ideal for
the study of smoking-induced carcinogenesis. Specifically, in early
stage adenocarcinoma tissue we compared gene expression from
current (C) and never (N) smokers and identified the major genes
using stringent criteria for gene selection (p,0.001 and fold
change .1.5), the Benjamini-Hochberg procedure[2] to calculate
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the False Discovery Rate (FDR), and Gene Ontology (GO)[3] to
classify the gene functional categories. We then verified whether
the comparison between former (F) and never (N) smokers
identified similar genes. We performed Gene Set Enrichment
Analysis (GSEA)[4] to identify common gene patterns where the
single-gene analysis revealed only few overlapping genes. We
further explored whether the genes that differentiated lung
tumors of smokers from never smokers (C/N and F/N) also
differentiated early stage tumor tissue (T) from paired non-tumor
(NT) tissue to confirm the role of these genes in smoking-related
lung carcinogenesis. We finally explored the impact of the
smoking signature on survival from lung cancer in smokers. We
validated C/N genes by Real Time-PCR in 68 samples used for
the present microarray analysis, and confirmed them in 40
independent samples from EAGLE and a Mayo Clinic study of
lung cancer.
Materials and Methods
Study population and sample collection
This study included 105 subjects from EAGLE, a large
population-based study of lung cancer conducted in the Lombardy
region of Italy. EAGLE lung cancer cases were enrolled from the
following 13 hospitals: A.O. Ospedale Niguarda Ca’ Granda,
Milano; A.O. Spedali Civili, Brescia; Istituto Clinico Humanitas,
Rozzano (MI); Ospedale di Circolo e Fondazione Macchi, Varese;
Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli
and Regina Elena, Milano; Istituto Scientifico Universitario
Ospedale San Raffaele, Milano; A.O. Ospedale Luigi Sacco,
Milano; A.O. San Paolo, Milano; A.O. Ospedale San Carlo
Borromeo, Milano; IRCCS Policlinico San Matteo, Pavia; A.O.
San Gerardo, Monza; A.O. Ospedale Fatebenefratelli, Milano;
Ospedale San Giuseppe, Milano. The healthy controls in EAGLE
were randomly selected from the same residential area of the lung
cancer cases. After description of the EAGLE study by the study
personnel, and discussion with potential participants, written
informed consent was obtained under a protocol approved by the
Institutional Review Board of each participating hospital and by
the National Cancer Institute (Bethesda, MD). Subjects in this
gene expression study, 44–79 years old, had histologically
confirmed primary adenocarcinoma of the lung, stages I–IV,
and provided detailed smoking and medical history information.
Overall, 180 adenocarcinoma and non-tumor tissue samples
were selected for the analyses, including duplicate or triplicate
samples from 14 subjects for quality control. Samples had been
snap-frozen in liquid nitrogen within 20 minutes of surgical
resection. A single pathologist confirmed the hospital-based
diagnosis of adenocarcinoma, estimated the presence of malignant
cells in each sample based on H&E-stained fresh frozen sections,
and classified the samples as Tumor (T) and Non-Tumor (NT).
From the original 180 samples, 148 provided sufficient quantity of
high-quality RNA for microarray analyses; 13 additional samples
were excluded because of technical problems. Normalization was
conducted on the remaining 135 microarrays; corresponding CEL
files and information conform to the MIAME guidelines are
publicly available on the GEO database (accession num-
ber =GSE10072). After normalization, 13 samples were excluded
because of low percentage of tumor cells in the tumor tissues. This
report is based on 122 samples, of which 15 duplicates/triplicates
were averaged, resulting in 107 final expression values from 58
tumor and 49 non-tumor tissues from 20 never smokers, 26 former
smokers, and 28 current smokers. Quality assurance and
distribution of cell types across smoking groups are described in
Appendix S1A, S1B, and S1C.
Statistical analysis
All statistical analyses were accomplished using R program
language. Gene expression data were processed and normalized
using Bioconductor Affy package, based on the Robust Multichip
Average (RMA) method[5] for single-channel Affymetrix chips.
All 22,283 probe sets based on RMA summary measure were used
in class comparison analyses.
Average linkage hierarchical clustering of samples was based on
one minus Pearson correlation as the dissimilarity metric.
An ANOVA analysis adjusting for sex was used to test whether
genes were differentially expressed between smoking groups (C/N
and F/N), between tumor tissue and non-tumor tissue (T/NT), or
by pack years of cigarette smoking. Further analyses adjusted by
tumor grade or excluding 6 subjects with emphysema or chronic
bronchitis or 3 subjects who received chemotherapy prior to the
study were conducted, with essentially unaltered results. For
analyses including paired tissues (T/NT tissue samples from the
same subjects), a linear mixed effects model was used to account
for intra-person correlation.
To limit false positive findings, genes were considered
statistically significant if their p-values were less than the stringent
threshold of 0.001. Under the null hypothesis of no difference in
expression profiles, and considering the analysis of 22,283 probes,
we expect that by chance the average number of false positive
findings will be #23. We used the Benjamini-Hochberg[2]
procedure to calculate the False Discovery Rate (FDR). We
further restricted significant genes to those which showed at least
1.5 fold ratio of geometric means of expression between two
groups. Gene selection based on p,0.001 (two-sided) and fold-
change .1.5 are referred to as ‘‘stringent criteria’’.
The Cox Proportional Hazards model[6] was used to estimate
the effect of gene expression changes in C/N on survival from
lung cancer in smokers. Of the 74 subjects included in this study
(all stages), 34 (22 smokers) were alive, and 40 (32 smokers) were
deceased as of May 2007. Among the deceased subjects, 36 died of
lung cancer. The remaining 4 (2 smokers) died of other cancers
and were censored at time of death in the analysis. The time from
lung cancer to death or date of last follow-up was between 28 days
and 5.0 years for the deceased subjects, and 3.7 and 5.7 years for
the subjects alive in May 2007. The relative risk of gene expression
was defined as the hazard ratio associated with one standard
deviation change of the expression. Analyses were adjusted for
stage, sex, and smoking. Age was similarly distributed across the
groups and was not adjusted for in the analysis.
Analysis of total plasma cotinine concentration by gas
chromatography/mass spectrometry
We verified the self-reported current smoking status by measuring
plasma cotinine levels. The total cotinine (free plus cotinine N-
glucuronide) concentration in plasma was quantified by GC/MS
analysis using a method similar to that used for urinary cotinine,[7]
with the addition of a solid phase extraction step carried out on an
MCX column (Waters Corporation, Milford, MA).
One individual who reported to have quit smoking 2.6 years
before the study had high cotinine levels (135 ng/ml) and was re-
classified as a current smoker.
Gene Set Enrichment Analysis
Gene Set Enrichment Analysis (GSEA)[4] was used to compare
expression in groups of genes (gene-sets), between different tissues or
between different comparison groups within the same tissue. GSEA
analysis reveals a pattern of common gene-sets even when single-gene
analysis reveals very few overlapping genes between groups. We
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modified the standard GSEAmethod by substituting an ANOVA test
for the standard two-sample t-test to adjust for sex. Furthermore, we
changed the permutation test for calculating the p-values by
permuting residuals and using as weights the observed ANOVA
coefficients divided by the standard error values. Up- and down-
regulated genes were included in different gene-sets for the analyses.
Molecular function classification of smoking-altered
genes
Gene Ontology was used to assign the genes to functional
categories.[3] GoMiner[8] was utilized to rank-order the GO
categories for the genes identified in the smoking comparisons.
Quantitative PCR validation and confirmation in
independent samples
We used quantitative real-time PCR (QRTPCR) to confirm the
differential expression of 19 C/N selected genes (20 probes),
including 14 genes from T and 5 from NT analyses. Primer and
probe sets for the selected genes as well as control probes for
GUSB and S18 (ABI) were run on 7500 Taqman under the
manufacturer’s standard protocol. Ct values were normalized
based on GUSB expression.
Validation assays were performed in 68 samples used in the
original microarray analyses, including 43 T (27 C and 16 N
smokers), and 25 NT (18 C and 7 N smokers).
Confirmation assays were performed in 40 independent samples,
including 19 T (12 C and 7 N smokers) and 21 NT samples (12 C
and 9 N smokers). These samples were collected in EAGLE (10 T
samples from 7 C and 3 N smokers, and 12 NT samples from 7 C
and 5 N smokers-these samples were not used for the microarray
analyses), and from theMayo Clinic, Rochester, MN (9T and 9NT
paired samples from 5 C and 4 N smokers).
Results
The molecular signature of cigarette smoking in lung
adenocarcinoma
To investigate the molecular changes associated with smoking in
the tumor tissue, we compared gene expression changes between
current and never (C/N) smokers (Table 1). To avoid potential
alteration of gene expression due to advanced tumor status, we
limited smoking comparisons in tumor tissue to the early stages
(stages I and II). Unless specified differently, ‘‘T’’ samples represent
early stage adenocarcinomas. Results from the advanced tumor
stage tissues are reported for completeness in Appendix S2C.
Using stringent selection criteria (fold-change .1.5 and p-
value,0.001), we identified 64 up- and 98 down-regulated probe-
sets, representing 54 up- and 81 down-regulated genes (Appendix
S2A, S2B). Most of the significantly up-regulated genes were
involved in cell cycle/mitosis/cell division (e.g., TTK, CENPF,
NEK2), while many of those down-regulated were involved in cell
adhesion/cell cycle arrest (e.g., ADRB2, APLP2, MACF1),
consistent with a role of these genes in neoplasia development.
The GoMiner results (Appendix S2D) confirmed that the mitosis
genes (12 altered genes among the 127 mitotic genes on the HG-
U133A chip, p,0.001), and more generally those involved in cell
cycle were the most commonly altered in the tumor tissue (Table 2).
Lung cancer gene expression is similar in current and
former smokers
To verify whether the C/N smoking signature in the tumor was
present also in former smokers, we compared the C/N and F/N
signatures in T and found 26 probes (22 down- and 4 up-
regulated, representing 21 genes) that differentiated both C/N
and F/N using stringent selection criteria (Appendix S2E). Some
of these genes, e.g., STOM, SSX2IP, TRPC6, APLP2 (2 probes),
and DHRS7, exhibited a persistent alteration even in subjects
(n = 6) who quit smoking more than 20 years before the study. The
GSEA analysis showed that among the 64 up- and 98 down-
regulated probes found in the C/N comparison in T, 58 and 90
probes, representing 50 up- and 73 down-regulated genes, were
also up- and down-regulated, respectively in the F/N smoking
comparison (p,0.001, Fig. 1, and Appendix S2F, S2G). All cell
cycle genes that differentiated C/N were also altered in F/N,
although less prominently (Table 2), indicating that alterations of
these genes persist following smoking cessation. Importantly, the
mitosis/cell cycle genes identified in C/N and F/N also
differentiated the early stage tumor from the non-tumor tissue
samples (T/NT, paired analysis) (Table 2), while pack years of
cigarette smoking, a composite index of intensity and duration that
does not consider the time when smoking occurred, were not
associated with gene expression in either T or NT.
Smoking signature in the noninvolved lung tissue
The C/N comparison in NT revealed 28 up- and 75 down-
regulated probes, representing 25 up- and 73 down-regulated
Table 1. Number of probes and genes differentiating current from never smokers (C/N) and former from never smokers (F/N) in all
tumor samples, early stage tumor samples (T), and all non-tumor (NT) tissue samples.
Criteria for
significance All stages Tumor Stages I and II Tumor (‘‘T’’) Non-Tumor (‘‘NT’’)
Comparison
between smokers
24 Current vs.
16 Never
18 Former vs.
16 Never
20 Current vs.
10 Never
13 Former vs.
10 Never
16 Current vs.
15 Never
18 Former vs.
15 Never
FDRa 8.5% 17.0% 9.5% 27.8% 7.8% 78.3%
Direction Down Up Down Up Down Up Down Up Down Up Down Up
p-value,0.001 Probes 142 119 25 105 126 106 31 40 211 71 7 2
Genes 119 104 22 97 104 89 25 35 191 64 7 2
p-value,0.001+
Fold change.1.5
Probes 61 63 17 3 98 64 26 4 75 28 1 0
Genes 48 56 15 3 81 54 21 4 73 25 1 0
aFDR = False Discovery Rate [2]
doi:10.1371/journal.pone.0001651.t001
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genes with the stringent selection criteria (Table 1, and Appendix
S3A, S3B). As expected, the CYP1B1 gene, known to be induced
by smoking[9,10] was strongly up-regulated. The GoMiner results
showed that the most smoking-altered genes were involved in
cellular defense response (5 of 90 cellular defense genes on the
chip, p,0.001), and more generally in immune response
(Appendix S3C).
MACF1, UBE21, and CBX7 (p,0.001), and C16orf30
(p = 0.001) were shared between T and NT C/N comparisons.
C16orf30 and UBE21, both on chromosome 16p13.3, are located
within 246kb, but they do not appear to share specific
transcriptional regulation mechanisms (Appendix S4A). The
GSEA analysis revealed some similarities between T and NT in
the overall pattern of smoking-induced alteration (p = 0.08 and
0.04, for up- and down-regulated genes, respectively, Appendix
S4B, S4C, and S4D). Notably, NEK2 and TTK were among
those similarly altered in both T and NT in the GSEA analysis. In
contrast, the F/N comparison in NT showed no statistically
significant genes (Table 1), and was not further explored.
Smoking-associated gene expression signature and
survival from lung cancer
We studied the overall gene expression signature of smoking in
T and NT (98+64 C/N in T, 75+28 C/N in NT, minus 3
overlapping probes between T and NT, for a total of 262 probe-
sets representing 230 genes) in relation to survival from
adenocarcinoma in smokers (n = 54, Appendix S5A). Since only
262 probe-sets were included in this analysis, we used a less
stringent criterion of p,0.01 for gene selection (Table 3). Altered
expression in NT of genes involved in the mitotic spindle
formation, e.g., NEK2 (p,0.001) and TTK (p=0.001) were
associated with a 3-fold increased mortality risk (Table 3, analysis
adjusted for stage, sex, and smoking).
Validation and confirmation of gene expression smoking
signature
We selected 19 genes (20 probes) for validation by QRTPCR,
including 14 genes for T and 5 for NT tissue, based on fold change
(.2) and cancer relevance.
Table 2. Cell cycle genes differentiating current from never smokers (C/N) in the early stage tumor (T) tissue samples, and
corresponding values in the former/never smoker (F/N) and in the smokers’ paired tumor/non-tumor tissue (T/NT) comparisons.
Probe ID Gene Chromosomal Current/Never{ N=30 Former/Never N=23 Tumor/Non-Tumor N=36
Symbol Location Fold-change p-value Fold-change p-value Fold-change p-value
204641_at NEK2* 1q32.2–q41 3.45 0.0001 2.84 0.0036 3.14 ,0.0001
204822_at TTK* 6q13–q21 3.27 ,0.0001 2.08 0.0123 2.22 ,0.0001
218009_s_at PRC1* 15q26.1 2.99 0.0007 2.61 0.0109 2.60 ,0.0001
207828_s_at CENPF* 1q32–q41 2.88 ,0.0001 2.28 0.0034 2.77 ,0.0001
202095_s_at BIRC5* 17q25 2.72 0.0002 2.10 0.0145 2.55 ,0.0001
203362_s_at MAD2L1 4q27 2.67 0.0003 1.93 0.0309 2.74 ,0.0001
219918_s_at ASPM 1q31 2.59 0.0008 2.12 0.0218 2.87 ,0.0001
210559_s_at CDC2 10q21.1 2.54 0.0009 2.02 0.0298 2.37 ,0.0001
201897_s_at CKS1B 1q21.2 2.36 0.0002 1.89 0.0152 2.47 ,0.0001
204170_s_at CKS2 9q22 2.36 0.0006 2.02 0.0148 1.69 0.0015
222077_s_at RACGAP1* 12q13.12 2.35 0.0003 1.91 0.0178 2.13 ,0.0001
203214_x_at CDC2 10q21.1 2.29 0.0006 1.98 0.0150 2.12 ,0.0001
219306_at KIF15* 3p21.31 2.22 0.0002 2.00 0.0047 1.90 0?0001
209642_at BUB1* 2q14 2.17 0.0009 1.68 0.0507 2.02 0.0001
210052_s_at TPX2* 20q11.2 2.06 0.0006 1.87 0.0100 2.07 ,0.0001
203418_at CCNA2 4q25–q31 1.99 ,0.0001 1.85 0.0012 1.82 ,0.0001
212020_s_at MKI67 10q25-qter 1.95 ,0.0001 1.71 0.0016 1.41 0.0006
201088_at KPNA2 17q23.1–q23.3 1.82 ,0.0001 1.53 0.0079 2.34 ,0.0001
211519_s_at KIF2C* 1p34.1 1.78 0.0004 1.67 0.0062 1.51 0.0002
218252_at CKAP2 13q14 1.75 0.0008 1.52 0.0292 1.47 0.0001
204887_s_at PLK4 4q27–q28 1.74 0.0001 1.55 0.0066 1.48 ,0.0001
211080_s_at NEK2* 1q32.2–q41 1.57 0.0001 1.50 0.0019 1.36 0.0002
214894_x_at MACF1 1p32–p31 0.65 0.0003 0.64 0.0016 0.52 ,0.0001
208634_s_at MACF1 1p32–p31 0.60 0.0001 0.58 0.0004 0.42 ,.0.0001
202284_s_at CDKN1A 6p21.2 0.54 0.0003 0.70 0.0668 0.65 0.0082
208893_s_at DUSP6 12q22–q23 0.34 0.0003 0.32 0.0012 0.84 0.3102
{Probe selection restricted to estimates with p,0.001 and fold-change .1.5 or ,0.6667, and within the most inclusive category of genes with p#0.001 in the GoMiner
analysis (GO ID 7049, Appendix S2D).
*Genes involved in the mitotic spindle formation. The double line separates up-regulated and down-regulated probes.
doi:10.1371/journal.pone.0001651.t002
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Validation was based on 68 samples, including 43 T and 25
NT, also used for the microarray analysis. All 19 genes were up-
regulated in the C/N comparison in these samples (Table 4).
Confirmation was based on 40 independent samples (19 T and
21 NT) from EAGLE (samples not used for microarray analysis)
and the Mayo Clinic, Rochester, MN. All the 14 genes in T and 4
of 5 genes in NT were up-regulated by smoking also in the
independent samples (Table 4).
Discussion
In a population-based study with fresh frozen tissue samples of
adenocarcinoma and noninvolved lung tissue (mostly paired
samples), we identified a smoking signature that persists years
after smoking cessation and is related to lung cancer development
and survival.
Aneuploidy and chromosome instability are two of the most
common abnormalities in cancer cells that arise through unequal
segregation of chromosomes between daughter cells during
mitosis. Thus, mitotic alterations are highly relevant for carcino-
genesis. We found that smoking induces deregulation of this very
mitotic process proceeding from lung tissue changes through
cancer development to cancer death or survival. In fact, the
smoking signature we identified comprises genes that regulate the
mitotic spindle formation. These genes, such as NEK2[11,12] and
CENPF[11] (both on 1q32-q41), TPX2[13,14] and STK6 (or
AURKA)[15] (related to the Aurora-A activation pathway
important in tumor progression[16]), TTK (linked to cell mitosis
through EGFR,[17] a critical drug target for lung adenocarcino-
ma[18]), and BIRC5 (Survivin),[19] have all been found over-
expressed in smoking-related tumors. While previous studies have
proposed these genes as targets for therapeutic interven-
tions,[16,18–21] our work suggests that they may be targets for
chemoprevention in smokers as well. In fact, they were strongly
induced by smoking in the early stage tumor tissue and some, e.g.,
NEK2 and TTK, were also associated with increased mortality
Figure 1. Comparison of gene expression differentiating current from never smokers (C/N) and gene expression differentiating
former from never smokers (F/N) in early stage tumor tissue (T) using Gene Set Enrichment Analysis (GSEA). Left: Running Enrichment
Score (y axis) is calculated by walking down the entire list of probes from Affymetrix HG-U133A chip (numbered from 1 to 22,283 in the x axis)
ordered by the ANOVA coefficients divided by the standard error values from the Former/Never (F/N) smoking comparison. This running-sum statistic
increases when a given probe is in the Current/Never (C/N) Gene Set of interest and decreases when the probe is not in the C/N Gene Set, with the
magnitude of increment depending on the strength of the correlation between the probe and the F/N comparison. The Enrichment Score (ES) is the
maximum deviation of the Running Enrichment Score from zero encountered in the random walk and reflects the degree to which the Gene Set is
overrepresented at the extremes (top or bottom) of the entire ranked probe list. We report results for two different C/N Gene Sets: on the top, the 64
up-regulated probes, with ES = 0.87 and, on the bottom, the 98 down-regulated probes, with ES=20.90. A leading edge subset of the Gene Set is
defined as those probes in the Gene Set that appear in the probes ranked list at, or before, the point where the running sum reaches its maximum
deviation from zero. The leading edge for the Gene Set of the C/N up-regulated probes contains 58 probes over 64 and the leading edge for the Gene
Set of down-regulated probes contains 90 over 98 probes. This confirms that among the 64 up-regulated probes from the C/N comparison, 58 are
also found in the F/N comparison; and among the 98 down-regulated probes from the C/N comparison, 90 are also found in the F/N comparison.
Right: distributions of ES values created using a permutation procedure for (top) the Gene Set of up-regulated probes in C/N and (bottom) the Gene
Set of down-regulated probes in C/N. These distributions are used to calculate the statistical significance (nominal p-value) of the observed ES values
(p-value,0.002 in both cases).
doi:10.1371/journal.pone.0001651.g001
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risk. The latter finding was most evident in non-tumor tissue, likely
reflecting the widely recognized field-cancerization effect by
smoking,[22] while in the tumor tissue, smoking-related genes’
effects on survival may be masked by extensive molecular
alterations occurring during tumorigenesis.
In the non-tumor tissue, current smoking strongly altered
immune response genes, consistent with the defense mechanisms
of the lung tissue against the acute toxic effects of smoking. Among
the gene most strongly down-regulated in NT was CX3CR1,
located on chromosome 3p21.3, an area known to be often deleted
in lung cancer,[23] particularly in smokers.[24]
Current knowledge of gene expression altered by cigarette
smoking is based on bronchoscopy-obtained airway epithelial cells
or macrophages[9,25–27] or peripheral leukocytes[10] from
healthy smokers rather than directly on lung tissue. The few
studies with lung tissue samples are very small[28] or used RNA
amplification[29] or RNA pooling[30] methods. Our results are
consistent with some previous findings, such as smoking-related
alteration of CYP1B1[9,10] or of the mitotic pathway in cancer
survival.[29] However, earlier studies were often limited by the
small sample size, or lacked information on potential confounders,
or availability of paired tumor and non-tumor lung tissue samples
for the distinction of gene changes involved in lung carcinogenesis
from those representing a transient smoking effect. We overcame
these pitfalls with a relatively large sample size of fresh tumor and
non-tumor lung tissues, detailed covariate information (e.g., sex,
age, stage, previous lung diseases or chemotherapy), biochemical
validation of the smoking status, and confirmation of the main
findings in independent tissue samples.
In conclusion, our study provides clues on how cigarette
smoking affects lung cancer development and survival. Functional
assays to confirm these findings are warranted. If confirmed, these
genes could become important targets for chemoprevention and
treatment for lung cancer in smokers.
Supporting Information
Appendix S1 Quality Assurance. 1A Description of analysis of
sample quality assurance 1B Samples’ description 1C Surfactant
genes in Tumor (T) and Non-Tumor (NT) lung tissues by smoking
Found at: doi:10.1371/journal.pone.0001651.s001 (0.07 MB
DOC)
Appendix S2 Current/Never (C/N) and Former/Never (F/N)
smoking comparisons in early stage Tumor (T) tissue. 2A Current/
Never (C/N) comparison, early stage Tumor (T) tissues: up-
regulated probes. 2B Current/Never (C/N) comparison, early
stage Tumor (T) tissues: down-regulated probes. 2C Current/
Never (C/N) comparison, late stage Tumor tissues: up+down-
regulated probes. 2D Gene Ontology (GO) functional categories
for the Current/Never (C/N) smoker comparison. 2E Current/
Never (C/N) and Former/Never (F/N) comparisons: overlapping
probe list. 2F Gene list from GSEA comparison of up-regulated
C/N genes and F/N genes in early stage Tumor (T) tissues. 2G
Gene list from GSEA comparison of down-regulated C/N genes
and F/N genes in early stage Tumor (T) tissues.
Found at: doi:10.1371/journal.pone.0001651.s002 (0.62 MB
DOC)
Appendix S3 Current/Never (C/N) smoking comparisons in
Non-Tumor (NT) lung tissue. 3A Current/Never (C/N) compar-
ison in Non-Tumor (NT) lung tissues: up-regulated probes. 3B
Current/Never (C/N) comparison in Non-Tumor (NT) lung
tissues: down-regulated probes . 3C Gene Ontology (GO)
functional categories for the Current/Never (C/N) comparison
(up and down-regulated genes) in Non-Tumor (NT) lung tissues.
Found at: doi:10.1371/journal.pone.0001651.s003 (0.21 MB
DOC)
Appendix S4 Comparison between Tumor (T) and Non-Tumor
(NT) lung tissue for the genes whose expression significantly
Table 3. Mortality risk in smokers for gene expression differentiating current from never smokers (C/N) in lung tumor and non-
tumor tissue samples (p,0.01)
Probe ID Gene Symbol p-value RRa 95% CIb Lowest 95% CIb Highest Tissue typec
Increased risk
204641_at NEK2 0.0008 2.6 1.5 4.7 NT
204822_at TTK 0.0011 2.9 1.5 5.5 NT
201292_at TOP2A 0.0041 3.1 1.4 6.7 NT
219306_at KIF15 0.0048 2.8 1.4 5.9 NT
218542_at C10orf3 0.0068 2.7 1.3 5.4 NT
209642_at BUB1 0.0084 2.8 1.3 5.9 NT
201637_s_at FXR1 0.0007 2.8 1.5 5.0 T
213189_at DKFZp667G2110 0.0088 2.0 1.2 3.4 T
Decreased risk
202068_s_at LDLR 0.0068 0.5 0.3 0.8 NT
214894_x_at MACF1 0.0091 0.4 0.2 0.8 NT
218804_at TMEM16A 0.0095 0.4 0.2 0.8 NT
201651_s_at PACSIN2 0.0046 0.4 0.2 0.8 T
aRelative Risk of death. Analysis based on 54 current and former smokers using 262 probes from the Current/Never smoking comparisons (98 down- and 64 up-
regulated probes from T and 75 down- and 28 up-regulated probes from NT, minus 3 overlapping probes in T and NT); models adjusted for tumor stage, sex, and
smoking status
b95% Confidence Interval
cT = Lung adenocarcinoma samples of any stage (N = 42); NT =Non-Tumor tissue samples (N = 34)
doi:10.1371/journal.pone.0001651.t003
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differentiates Current from Never smokers (C/N) in early stage lung
Tumor (T). 4A C16orf30 and UBE21 transcription sites. 4B
Comparison of C/N results in early stage Tumor (T) tissues vs. C/
N results in Non-Tumor (NT) lung tissues by GSEA analysis. 4C
Gene list from GSEA comparison of up-regulated C/N genes
between early stage Tumor (T) tissues and Non-Tumor (NT) tissues.
4D Gene list from GSEA comparison of down-regulated C/N genes
between early stage Tumor (T) tissues and Non-Tumor (NT) tissues.
Found at: doi:10.1371/journal.pone.0001651.s004 (0.51 MB
DOC)
Appendix S5 Mortality risk in smokers associated with the
expression of genes differentiating Current from Never smokers
(C/N) in Tumor and Non-Tumor tissue samples. 5A Current/
Never (C/N) genes and related mortality risk in Tumor and Non-
Tumor lung tissues (all stages) from Current and Former smokers.
Found at: doi:10.1371/journal.pone.0001651.s005 (0.55 MB
DOC)
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